Such detrimental outcomes are not reported in patients receiving chemo-immunotherapy combinations, which also demonstrated efficacy compared to chemotherapy alone as a first-line treatment of NSCLC, regardless of PD-L1 expression [9,10,11]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.